These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 35353605)

  • 1. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
    Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein.
    Elfarrash S; Jensen NM; Ferreira N; Schmidt SI; Gregersen E; Vestergaard MV; Nabavi S; Meyer M; Jensen PH
    PLoS One; 2021; 16(10):e0252635. PubMed ID: 34613964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
    Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
    Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils.
    Hmila I; Sudhakaran IP; Ghanem SS; Vaikath NN; Poggiolini I; Abdesselem H; El-Agnaf OMA
    ACS Chem Neurosci; 2022 Dec; 13(23):3330-3341. PubMed ID: 36348612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
    Fayyad M; Erskine D; Majbour NK; Vaikath NN; Ghanem SS; Sudhakaran IP; Abdesselem H; Lamprokostopoulou A; Vekrellis K; Morris CM; Attems J; El-Agnaf OMA
    Brain Pathol; 2020 Jul; 30(4):831-843. PubMed ID: 32324926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
    Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
    PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
    Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
    Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
    Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
    Oueslati A
    J Parkinsons Dis; 2016; 6(1):39-51. PubMed ID: 27003784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.
    Samuel F; Flavin WP; Iqbal S; Pacelli C; Sri Renganathan SD; Trudeau LE; Campbell EM; Fraser PE; Tandon A
    J Biol Chem; 2016 Feb; 291(9):4374-85. PubMed ID: 26719332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice.
    Butler YR; Liu Y; Kumbhar R; Zhao P; Gadhave K; Wang N; Li Y; Mao X; Wang W
    Nat Commun; 2022 Jul; 13(1):4060. PubMed ID: 35853942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
    Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.
    Wu J; Lou H; Alerte TN; Stachowski EK; Chen J; Singleton AB; Hamilton RL; Perez RG
    Neuroscience; 2012 Apr; 207():288-97. PubMed ID: 22326202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease.
    Zhang S; Liu YQ; Jia C; Lim YJ; Feng G; Xu E; Long H; Kimura Y; Tao Y; Zhao C; Wang C; Liu Z; Hu JJ; Ma MR; Liu Z; Jiang L; Li D; Wang R; Dawson VL; Dawson TM; Li YM; Mao X; Liu C
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34172566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.
    Donadio V; Incensi A; El-Agnaf O; Rizzo G; Vaikath N; Del Sorbo F; Scaglione C; Capellari S; Elia A; Stanzani Maserati M; Pantieri R; Liguori R
    Sci Rep; 2018 Sep; 8(1):14246. PubMed ID: 30250046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.